Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019, 163(1):45-53 | DOI: 10.5507/bp.2018.036

Increased glutamate and deep brain atrophy can predict the severity of multiple sclerosis

Hubert Polaceka, Ema Kantorovab, Petra Hnilicovac, Marian Grendarc, Kamil Zelenakd, Egon Kurcab
a Clinic of Nuclear Medicine, Jessenius Faculty of Medicine in Martin, Comenius University Bratislava, Slovak Republic
b Clinic of Neurology, Jessenius Faculty of Medicine in Martin, Comenius University Bratislava, Slovak Republic
c Biomedical Centre, Jessenius Faculty of Medicine in Martin, Comenius University Bratislava, Slovak Republic
d Clinic of Radiodiagnostics, Jessenius Faculty of Medicine in Martin, Comenius University Bratislava, Slovak Republic

Objective: In multiple sclerosis (MS), deep grey matter (DGM) atrophy has been recognised as a crucial component of the disease that presents early and it has been associated with disability. Although the precise mechanism underlying grey matter atrophy is unknown, several hypotheses have been postulated. Our previous research pointed to correlations of hypothalamic metabolic alterations with clinical outcomes of MS, therefore we decided to further test the relationship of these alterations with DGM atrophy.

Methods: We used 1H-Magnetic Resonance spectroscopy (1H-MRS) of the hypothalamus to test its metabolites in 26 patients with RRMS and 22 healthy age-matched controls. DGM atrophy was evaluated by simple planimetry of third ventricular width on the hypothalamic level (3VW) in T1 weighted MRI pictures. Metabolite ratios of N-acetyl aspartate (NAA), choline (Cho), glutamate and glutamine (Glx), myo-inositol (mIns) and creatine (Cr) were correlated with Multiple Sclerosis Severity Scale (MSSS) and 3VW.

Results: Metabolite concentrations were compared between patients and controls using multiple regression models allowing for age, 3VW and metabolites. It revealed that the only relevant predictors of MSSS were 3VW and Glx/NAA. At a significance level of P<0.05, a unit increase of 3VW was associated with a 0.35 increase of MSSS, for a typical value of Glx/NAA; P value 0.0039. A unit increase of Glx/NAA was associated with a 0.93 increase of MSSS, for a typical value of atrophy; P value 0.090. There were significant linear correlations between Glx/Cr and MSSS, Glx/NAA and MSSS, and between mIns/NAA and 3VW.

Conclusions: The results suggest that both NAA and Glx are associated with neurodegeneration of hypothalamic DGM and severe disease course. Glx related 1H-MRS parameters seem to be superior to other metabolites in determining disease burden, independently of otherwise powerful 3VW planimetry. Significantly increased mIns/NAA in MS patients compared to controls point to gliosis, which parallels the atrophy of hypothalamic DGM.

Keywords: multiple sclerosis, predictors, disease severity, neurodegeneration, 1H-MRS, brain metabolites, width of the third ventricle, brain atrophy

Received: February 10, 2018; Accepted: June 19, 2018; Prepublished online: July 16, 2018; Published: February 18, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Polacek, H., Kantorova, E., Hnilicova, P., Grendar, M., Zelenak, K., & Kurca, E. (2019). Increased glutamate and deep brain atrophy can predict the severity of multiple sclerosis. Biomedical papers, 163(1), 45-53. doi: 10.5507/bp.2018.036
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Miller DH. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. Neuro Rx 2004;1(2):284-94. Go to original source... Go to PubMed...
    2. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001;7:115-21. Go to original source... Go to PubMed...
    3. Haider L, Simeonidou C, Steinberger G, Hametner S, Grigoriadis N, Deretzi G, Kovacs GG, Kutzelnigg A, Lassmann H, Frischer JM. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry 2014;85:1386-95. Go to original source... Go to PubMed...
    4. Huitinga I, De Groot CJ, Van der Valk P, Kamphorst W, Tilders FJ, Swaab DF. Hypothalamic lesions in multiple sclerosis. J Neuropathol Exp Neurol 2001;60:1208-18. Go to original source... Go to PubMed...
    5. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology 2007;68:634-42. Go to original source... Go to PubMed...
    6. Neema M, Arora A, Healy BC, Guss ZD, Brass SD, Duan Y, Buckle GJ, Glanz BI, Stazzone L, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 2009;19:3-8. Go to original source... Go to PubMed...
    7. Wolinsky JS, Narayana PA, Fenstermacher MJ.Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990;40:1764-9. Go to original source... Go to PubMed...
    8. Helms G, Stawiarz L, Kivisäkk P, Link H. Regression analysis of metabolite concentrations estimated from localized proton MR spectra of active and chronic multiple sclerosis lesions. Magn Reson Med 2000;43:102-10. Go to original source... Go to PubMed...
    9. Caramanos Z, Narayanan S, Arnold DL. 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain 2005;128:2483-506. Go to original source... Go to PubMed...
    10. Azevedo CJ, Kornak J, Chu P, Sampat M, Okuda DT, Cree BA, Nelson SJ, Hauser SL, Pelletier D. In vivo evidence of glutamate toxicity in multiple sclerosis. Ann Neurol 2014;76:269-78. Go to original source... Go to PubMed...
    11. Llufriu S, Kornak J, Ratiney H, Oh J, Brenneman D, Cree BA, Sampat M, Hauser SL, Nelson SJ, Pelletier D. Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. JAMA Neurol 2014;71:840-7. Go to original source... Go to PubMed...
    12. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650-3. Go to original source... Go to PubMed...
    13. Clark JF, Doepke A, Filosa JA, Wardle RL, Lu A, Meeker TJ, Pyne-Geithman GJ.N-acetylaspartate as a reservoir for glutamate. Med Hypotheses 2006;67:506-12. Go to original source... Go to PubMed...
    14. Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y AcadSci 2008;1144:97-112. Go to original source... Go to PubMed...
    15. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1(8):623-34. Go to original source... Go to PubMed...
    16. Macrez R, Stys PK, Vivien D, Lipton SA, Docagne F. Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities. Lancet Neurol 2016;15(10):1089-102. Go to original source... Go to PubMed...
    17. Tisell A, Leinhard OD, Warntjes JB, Aalto A, SmedbyÖ, Landtblom AM, Lundberg P. Increased concentrations of glutamate and glutamine in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans. PLoS One 2013;8(4):e61817. Go to original source... Go to PubMed...
    18. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993;15:289-98. Go to original source... Go to PubMed...
    19. Chard DT, Griffin CM, McLean MA, Kapeller P, Kapoor R, Thompson AJ, Miller DH. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125:2342-52. Go to original source... Go to PubMed...
    20. Kirov II, Patil V, Babb JS, Rusinek H, Herbert J, Gonen O. MR spectroscopy indicates diffuse multiple sclerosis activity during remission. J Neurol Neurosurg Psychiatry 2009;80(12):1330-6. Go to original source... Go to PubMed...
    21. Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Miller DE, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE 3rd, Brownscheidle CM. A longitudinal study of brain atrophy in relapsing multiple sclerosis.The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1999;53:139-48. Go to original source... Go to PubMed...
    22. Benedict RH, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol 2004;61:226-30. Go to original source... Go to PubMed...
    23. Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergstrom J, Flodmark O, Aspelin P, KristoffersenWiberg M. Rate of ventricular enlargement in multiple sclerosis: a nine-year magnetic resonance imaging follow-up study. Acta Radiol 2008;49:570-9. Go to original source... Go to PubMed...
    24. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6. Go to original source... Go to PubMed...
    25. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-51. Go to original source... Go to PubMed...
    26. Jiru F, Skoch A, Wagnerova D, Dezortova M, Hajek M. jSIPRO - analysis tool for magnetic resonance spectroscopic imaging.Comput Methods Programs Biomed 2013;112:173-88. Go to original source... Go to PubMed...
    27. Kantorová E, Poláček H, Bittąanský M, Baranovičová E, Hnilicová P, Čierny D, Sivák ©, Nosáµ V, Zeleňák K, Kurča E. Hypothalamic damage in multiple sclerosis correlates with disease activity, disability, depression, and fatigue. Neurol Res 2017;39(4):323-30. Go to original source... Go to PubMed...
    28. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. 2015. https://www.R-project.org/.
    29. Fletcher TD. Psychometric: Applied Psychometric Theory. R package version 2. 2. 2010. https://CRAN.R-project.org/package=psychometric
    30. Diedenhofen B, Musch J. cocor: a comprehensive solution for the statistical comparison of correlations. PLoS One 2015;10:e0121945. Go to original source... Go to PubMed...
    31. Venables WN, Ripley BD. Modern Applied Statistics with S. 4th edition, Springer. New York. 2002. Go to original source...
    32. Lim CK, Brew BJ, Sundaram G, Guillemin GJ.Understanding the roles of the kynurenine pathway in multiple sclerosis progression. Int J Tryptophan Res 2010;3:157-67. Go to original source... Go to PubMed...
    33. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001;50:169-80. Go to original source... Go to PubMed...
    34. Pitt D, Nagelmeier IE, Wilson HC, Raine CS. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 2003;61:1113-20. Go to original source... Go to PubMed...
    35. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, Rudick R, Mirnics K, Trapp BD. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006;59:478-89. Go to original source... Go to PubMed...
    36. Baranzini SE, Srinivasan R, Khankhanian P, Okuda DT, Nelson SJ, Matthews PM, Hauser SL, Oksenberg JR, Pelletier D. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain 2010;133:2603-11. Go to original source... Go to PubMed...
    37. Geurts JJ, Wolswijk G, Bö L, van der Valk P, Polman CH, Troost D, Aronica E. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 2003;126:1755-66. Go to original source... Go to PubMed...
    38. Rossi S, Studer V, Moscatelli A, Motta C, Coghe G, Fenu G, Caillier S, Buttari F, Mori F, Barbieri F, Castelli M, De Chiara V, Monteleone F, Mancino R, Bernardi G, Baranzini SE, Marrosu MG, Oksenberg JR, Centonze D. Opposite roles of NMDA receptors in relapsing and primary progressive multiple sclerosis. PLoS One 2013;8(6):e67357. Go to original source... Go to PubMed...
    39. Zhou Y, Danbolt NC. GABA and Glutamate Transporters in Brain. Front Endocrinol (Lausanne) 2013;4:165. Go to original source... Go to PubMed...
    40. Hardingham GE, Bading H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci 2003;26:81-9. Go to original source... Go to PubMed...
    41. Müller M, Esser R, Kötter K, Voss J, Müller A, Stellmes P. Third ventricular enlargement in early stages of multiple sclerosis is a predictor of motor and neuropsychological deficits: a cross-sectional study. BMJ Open 2013;3(9):e003582. Go to original source... Go to PubMed...
    42. Butzkueven H, Kolbe SC, Jolley DJ, Brown JY, Cook MJ, van der Mei IA, Groom PS, Carey J, Eckholdt J, Rubio JP, Taylor BV, Mitchell PJ, Egan GF, Kilpatrick TJ. Validation of linear cerebral atrophy markers in multiple sclerosis. J Clin Neurosci 2008;15:130-7. Go to original source... Go to PubMed...
    43. Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC; 16-Year Long Term Follow-up Study Investigators. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:282-7. Go to original source... Go to PubMed...
    44. Shiee N, Bazin PL, Zackowski KM, Farrell SK, Harrison DM, Newsome SD, Ratchford JN, Caffo BS, Calabresi PA, Pham DL, Reich DS. Revisiting brain atrophy and its relationship to disability in multiple sclerosis. PLoS One 2012;7(5):e37049. Go to original source... Go to PubMed...
    45. Lansley J, Mataix-Cols D, Grau M, Radua J, Sastre-Garriga J. Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. Neurosci Biobehav Rev 2013;37(5):819-30. Go to original source... Go to PubMed...
    46. Geurts JJ, Reuling IE, Vrenken H, Uitdehaag BM, Polman CH, Castelijns JA, Barkhof F, Pouwels PJ. MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med 2006;55:478-83. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content